Zepbound for Sleep Apnea: FDA Approval, How It Works and Insurance Coverage

Zepbound's label lists two uses: weight reduction, and moderate to severe OSA in adults with obesity, both alongside a reduced-calorie diet and more physical activity.1 The label was most recently revised in August 2026.1 The FDA granted the OSA application Fast Track, Priority Review and Breakthrough Therapy designations.2

Moderate OSA in the trials meant an apnea-hypopnea index (AHI) of 15 to 30 events an hour, and severe meant 30 or more.1 Mounjaro contains the same active ingredient, tirzepatide, under a separate diabetes label; see Mounjaro vs Zepbound for how the two differ.

Zepbound is the GLP-1-based drug with an FDA-approved OSA indication; the FDA described it as the first drug treatment for the condition.2

Zepbound activates GLP-1 and GIP receptors to reduce appetite and food intake, which lowers body weight and, the FDA says, improves OSA.2 The SURMOUNT-OSA investigators describe excess body fat as a causal risk factor for OSA and proposed tirzepatide as a potential treatment.3

In the trials, Zepbound lowered the apnea-hypopnea index, the number of times breathing stops or becomes shallow per hour of sleep.1,3 It also reduced body weight, sleep apnea-specific hypoxic burden, systolic blood pressure and a marker of inflammation (hsCRP), and improved sleep-related patient-reported outcomes.1,3

In two 52-week trials of 469 adults with moderate to severe OSA and obesity, Zepbound cut breathing events by roughly half or more, against small changes on placebo.1,3 Study 5 enrolled people who could not or would not use positive airway pressure (PAP), and Study 6 enrolled people on PAP.1 Patients with type 2 diabetes were excluded.1

Source: Zepbound prescribing information, Table 9.1

Average baseline AHI was 51.5 events an hour in Study 5 and 49.5 in Study 6, and average BMI was about 39.1,3 Most adverse events with tirzepatide were gastrointestinal and mostly mild to moderate.3

The label does not say so. People in Study 6 paused PAP for 7 days before the main measurement, and the label states the trials did not evaluate the timing or appropriateness of stopping PAP in people who were using it.1 Any change to PAP therapy is a decision for your sleep physician.

Often it can, because OSA is a covered medical condition even on plans that exclude weight-loss drugs, but each plan sets its own rules.7 UnitedHealthcare's prior authorization program, effective October 1, 2026, lists Zepbound for moderate to severe OSA as an approved use.7 For plans that do not cover weight-loss medications, UnitedHealthcare points to separate non-formulary Zepbound criteria.7

Other insurers, including Aetna, Cigna, Humana and the Blue Cross Blue Shield companies, set their own criteria. Ask your plan:

1. Is Zepbound on the formulary for obstructive sleep apnea?
2. What does prior authorization require, such as a sleep study showing the AHI?
3. What is my copay or coinsurance at that tier?

If coverage is denied, compare cash options on our Zepbound cost page and our cheapest Zepbound ranking. Our full guide on whether insurance covers Zepbound covers plan by plan what is published.

Medicare Part D plans can cover Zepbound for sleep apnea, because Medicare may cover GLP-1s used for an FDA-approved indication other than obesity.5 Medicare has been barred by law from covering drugs used specifically for weight loss.5 KFF lists sleep apnea alongside type 2 diabetes and cardiovascular risk reduction as indications Part D plans can cover.5

People with moderate-to-severe sleep apnea are not eligible for the Medicare GLP-1 Bridge, the $50-a-month weight-loss program that started July 1, 2026.4 Medicare.gov says their regular Part D plan might cover their GLP-1 instead.4 That means the route for OSA is your own plan's formulary, tier and prior authorization, not the Bridge. Our Medicare GLP-1 coverage guide explains the Bridge rules.

Yes. State Medicaid programs are required to cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, even though covering GLP-1s for weight loss alone is optional for states.6 Prior authorization and preferred-drug rules still vary by state.6

You need a diagnosis of moderate to severe OSA and a prescription.1 The trials defined OSA severity by AHI on an overnight sleep study, which is also what a plan reviewing a prior authorization is likely to look for.1,7 Treatment then follows the standard escalation: 2.5 mg for 4 weeks, then up in 2.5 mg steps at least 4 weeks apart, to a maintenance dose of 10 mg or 15 mg.1 Our Zepbound dosage guide sets out every step.

If you are paying cash, telehealth programs that prescribe brand Zepbound are ranked on our best GLP-1 programs page.

Does Zepbound help with sleep apnea if you are not obese? The OSA approval covers adults with obesity, and the trials enrolled people with a BMI of 30 or more.1

How long does it take Zepbound to work for sleep apnea? The trials measured the main result at 52 weeks, after up to 20 weeks of dose escalation.1 See how long Zepbound takes to work.

Does tirzepatide help sleep apnea in people with type 2 diabetes? The OSA trials excluded people with type 2 diabetes, so the label's OSA results do not cover that group.1

What is the Zepbound dose for sleep apnea? The maintenance dose is 10 mg or 15 mg once weekly.1

Is Zepbound covered by insurance for sleep apnea if my plan excludes weight-loss drugs? It can be. UnitedHealthcare, for example, has separate non-formulary Zepbound criteria for plans that do not cover weight-loss drugs.7

Check your plan's OSA criteria first. If you will be paying out of pocket, our cheapest ways to buy Zepbound and the Zepbound savings card guide show where the price is lowest.

This article is for information only and is not medical, legal or financial advice. Coverage rules change. Confirm benefits with your health plan, Medicare or your state Medicaid agency, and talk to a licensed clinician or sleep specialist before starting or changing any treatment.